BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brennan BJ, Davies B, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, Aceves Baldó P, Lennon-Chrimes S, Rayner CR. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob Agents Chemother 2012;56:4729-37. [PMID: 22733065 DOI: 10.1128/AAC.00200-12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Kambayashi R, Goto A, Onozato M, Izumi-Nakaseko H, Takei Y, Matsumoto A, Kawai S, Fukushima T, Sugiyama A. Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model. J Pharmacol Sci 2022;148:179-86. [PMID: 34924124 DOI: 10.1016/j.jphs.2021.11.002] [Reference Citation Analysis]
2 Kaminski MM, Ohnemus A, Staeheli P, Rubbenstroth D. Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model. J Virol 2013;87:1912-5. [PMID: 23192869 DOI: 10.1128/JVI.02507-12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
3 Stockmann C, Spigarelli MG, Healy DP, Gottschlich MM, Kagan R, Balch AH, Sherwin C. Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos 2015;36:405-9. [PMID: 25766031 DOI: 10.1002/bdd.1949] [Reference Citation Analysis]
4 van der Vries E, Stittelaar KJ, van Amerongen G, Veldhuis Kroeze EJ, de Waal L, Fraaij PL, Meesters RJ, Luider TM, van der Nagel B, Koch B, Vulto AG, Schutten M, Osterhaus AD. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog 2013;9:e1003343. [PMID: 23717200 DOI: 10.1371/journal.ppat.1003343] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
5 Rayner CR, Smith PF, Hershberger K, Wesche D. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Clin Transl Sci 2020;13:830-4. [PMID: 32212378 DOI: 10.1111/cts.12790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Rowe E, Ng PY, Chandra T, Chen M, Leo YS. Seasonal Human Influenza: Treatment Options. Curr Treat Options Infect Dis 2014;6:227-44. [PMID: 32288650 DOI: 10.1007/s40506-014-0019-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Várkonyi I, Chappey C, Giraudon M, Burleigh L. A part-randomized study of intravenous oseltamivir in adolescents and adults. Eur J Clin Microbiol Infect Dis 2015;34:1181-8. [PMID: 25678009 DOI: 10.1007/s10096-015-2338-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kitano M, Itoh Y, Ishigaki H, Nakayama M, Ishida H, Pham VL, Arikata M, Shichinohe S, Tsuchiya H, Kitagawa N, Kobayashi M, Yoshida R, Sato A, Le QM, Kawaoka Y, Ogasawara K. Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob Agents Chemother 2014;58:4795-803. [PMID: 24913156 DOI: 10.1128/AAC.02817-14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
9 Gibiansky L, Giraudon M, Rayner CR, Brennan BJ, Subramoney V, Robson R, Kamal MA. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment. J Pharmacokinet Pharmacodyn 2015;42:225-36. [PMID: 25821064 DOI: 10.1007/s10928-015-9411-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
10 Sambi M, Samuel V, Qorri B, Haq S, Burov SV, Markvicheva E, Harless W, Szewczuk MR. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. Drug Des Devel Ther 2020;14:1995-2019. [PMID: 32546966 DOI: 10.2147/DDDT.S242514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Parker RB, Hu ZY, Meibohm B, Laizure SC. Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet 2015;54:627-38. [PMID: 25511794 DOI: 10.1007/s40262-014-0226-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
12 Hu ZY, Edginton AN, Laizure SC, Parker RB. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition. Clin Pharmacokinet 2014;53:825-36. [PMID: 25103325 DOI: 10.1007/s40262-014-0160-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]